CTCs are rarecancercells that tumors shed in the blood. They've been looked at before inprostate cancer, but only in its later stages. "No one, until now, has looked at whether CTC counts can be used right at the beginning, when a man first presents with metastatic prostatecancer, to ...
Blood Test Could Prevent Prostate Cancer Deaths
The Stockholm3 blood test, developed by researchers at Karolinska Institutet, is equally effective at detecting prostate cancer in different ethnic groups, a new paperpublishedin theJournal of Clinical Oncologyreports. The test produces significantly better results than the current PSA standard. Stockholm...
"There is currently no single test for prostate cancer, but PSA blood tests are among the most used, alongside physical examinations, MRI scans and biopsies. "However, PSA blood tests are not routinely used to screen for prostate cancer, as results can be unreliable. "Only about a quarter o...
Prostate Cancer Blood Test May Avert BiopsiesJody A. CharnowEditor
The prostate-specific antigen (PSA) test is used to measure blood PSA levels and help detect prostate cancer or other prostate abnormalities.
However, even a tiny increase, such as three or four CTCs in blood samples at week 12, was found to be associated with an average survival of 15 months. Study leader professor Johann de Bono said: “At the moment assess in the clinic how men with advanced prostate cancer are re...
analysis. It measures how much prostate-specific antigen you have in your blood. There's no set level to tell doctors whether you have prostate cancer. But the higher the level, the more likely you'll need further tests, such as a biopsy,MRI, or other lab tests to check for cancer. ...
In a large retrospective study of blood samples, the researchers showed that the method, called a "liquid biopsy," could accurately distinguishprostate cancerfrom normal controls without prior knowledge of the genetic "signature" of the tumors, and with over three times the sensitivity of current ...
Prostate cancer patients whose tumors contain a shortened protein called AR-V7, which can be detected in the blood, are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at